USPTO serial 90118411
N
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- LOBO, DEBORAH E
- Law office
- TMEG LAW OFFICE 109 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with N?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Doylestown, PA
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the prevention of chronic and neuropathic pain; Pharmaceutical preparations for the treatment and prevention of chronic and neuropathic pain; Pharmaceutical preparations for the treatment of chronic and neuropathic pain; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for wounds; Pharmaceutical preparations for central nervous system and peripheral nervous system disorders; Analgesic and muscle relaxant pharmaceutical preparations; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of central nervous system and peripheral nervous system disorders; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals | ACTIVE | — |
| 042 | Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Research in the field of central nervous system and peripheral nervous system disorders; Research in the field of central nervous system and peripheral nervous system disorders; Clinical research in the field of central nervous system and peripheral nervous system disorders; Development of pharmaceutical preparations and medicines; Laboratory research in the field of central nervous system and peripheral nervous system disorders; Medical and scientific research in the field of central nervous system and peripheral nervous system disorders; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Scientific research consulting in the field of cosmetics; Scientific research for medical purposes in the field of central nervous system and peripheral nervous system disorders; Scientific research in the field of central nervous system and peripheral nervous system disorders; Scientific study and research in the field(s) of central nervous system and peripheral nervous system disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 3, 2021 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 3, 2021 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 20, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 20, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 20, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 13, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 9, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 9, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 24, 2020 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Sep 24, 2020 | ALIE | ASSIGNED TO LIE | — |
| Sep 19, 2020 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Sep 18, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 25, 2020 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Aug 20, 2020 | NWAP | NEW APPLICATION ENTERED | — |